Last reviewed · How we verify
BEACOPPesc - ABVD - PET2
BEACOPPesc-ABVD-PET2 is a chemotherapy regimen combined with PET imaging to guide treatment intensity in Hodgkin lymphoma, using escalated BEACOPP and ABVD chemotherapy with PET-2 response assessment to tailor subsequent therapy.
BEACOPPesc-ABVD-PET2 is a chemotherapy regimen combined with PET imaging to guide treatment intensity in Hodgkin lymphoma, using escalated BEACOPP and ABVD chemotherapy with PET-2 response assessment to tailor subsequent therapy. Used for Hodgkin lymphoma, early-stage and advanced-stage (treatment guided by PET-2 response).
At a glance
| Generic name | BEACOPPesc - ABVD - PET2 |
|---|---|
| Sponsor | Centre Hospitalier Universitaire Dijon |
| Drug class | Combination chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This is a combined chemotherapy approach for Hodgkin lymphoma that alternates or combines bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP escalated) with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). PET imaging after 2 cycles (PET2) is used as a prognostic tool to identify early responders versus non-responders, allowing treatment intensification or modification based on metabolic response rather than fixed protocols.
Approved indications
- Hodgkin lymphoma, early-stage and advanced-stage (treatment guided by PET-2 response)
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Nausea and vomiting
- Alopecia
- Mucositis
- Cardiotoxicity (doxorubicin-related)
- Pulmonary toxicity (bleomycin-related)
- Peripheral neuropathy (vincristine-related)
- Infertility risk
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |